A PD-1 Inhibitor Induces Complete Response of Advanced Bladder Urothelial Carcinoma: A Case Report

被引：7

作者：

Wang, Jianzheng ^{[1
]}

Li, Qingli ^{[2
]}

Lv, Huifang ^{[1
]}

Nie, Caiyun ^{[1
]}

Chen, Beibei ^{[1
]}

Xu, Weifeng ^{[1
]}

Yang, Tiejun ^{[3
]}

Zhang, Yinping ^{[4
]}

Tu, Shuiping ^{[2
]}

Chen, Xiaobing ^{[1
]}

机构：

[1] Zhengzhou Univ, Dept Med Oncol, Affiliated Canc Hosp, Henan Canc Hosp, Zhengzhou, Peoples R China

[2] Shanghai Jiao Tong Univ, Renji Hosp, Sch Med, Dept Oncol, Shanghai, Peoples R China

[3] Zhengzhou Univ, Henan Canc Hosp, Dept Urol Surg, Affiliated Canc Hosp, Zhengzhou, Peoples R China

[4] Zhengzhou Univ, Henan Canc Hosp, Dept Pathol, Affiliated Canc Hosp, Zhengzhou, Peoples R China

来源：

FRONTIERS IN ONCOLOGY | 2021年 / 11卷

关键词：

PD-1; complete response; advanced; urothelial carcinoma; case report; CELL LUNG-CANCER; ADVERSE EVENTS; PNEUMONITIS; CHEMOTHERAPY; GEMCITABINE; CISPLATIN; TOXICITY; EFFICACY;

D O I：

10.3389/fonc.2021.671416

中图分类号：

R73 [肿瘤学];

学科分类号：

100214 ;

摘要：

The prognosis of patients with advanced urothelial carcinoma is dismal. Platinum-based chemotherapy is still the main first-line treatment for advanced urothelial carcinoma, while immunotherapy can be used as a first-line treatment option for people who cannot tolerate platinum. Immunotherapy is preferred in the second-line treatment of bladder urothelial carcinoma. PD-1 inhibitors (Pembrolizumab, nivolumab and atezolizumab) and PD-L1 inhibitors (Ddurvalumab and avelumab) have not been approved for the treatment of advanced urothelial cancer in China. We describe a patient with advanced urothelial carcinoma experienced disease progression after gemcitabine chemotherapy. Following a treatment of domestic PD-1 inhibitor (sintilimab), the patient achieved a durable complete response with mild toxicity. This case indicates that PD-1 inhibitor sintilimab might be a second-line treatment choice for advanced urothelial carcinoma.

引用

页数：7

共 28 条

[1] Osimertinib combined with durvalumab in EGFR-mutant non-small cell lung cancer: Results from the TATTON phase Ib trial [J].

Ahn, M. -J. ;

Yang, J. ;

Yu, H. ;

Saka, H. ;

Ramalingam, S. ;

Goto, K. ;

Kim, S. -W. ;

Yang, L. ;

Walding, A. ;

Oxnard, G. R. .

JOURNAL OF THORACIC ONCOLOGY, 2016, 11 (04) :S115-S115

[2] Sintilimab: another effective immune checkpoint inhibitor in classical Hodgkin lymphoma [J].

Ansell, Stephen M. .

LANCET HAEMATOLOGY, 2019, 6 (01) :E2-E3

[3] A Case of Long-Term Survival after Checkpoint Inhibitor Pneumonitis in a Patient with Squamous Cell Lung Cancer [J].

Ashinuma, Hironori ;

Mizuno, Satoko ;

Yoshida, Yasushi ;

Shingyoji, Masato .

CASE REPORTS IN ONCOLOGICAL MEDICINE, 2019, 2019

[4] Pembrolizumab as Second-Line Therapy for Advanced Urothelial Carcinoma [J].

Bellmunt, J. ;

de Wit, R. ;

Vaughn, D. J. ;

Fradet, Y. ;

Lee, J. -L. ;

Fong, L. ;

Vogelzang, N. J. ;

Climent, M. A. ;

Petrylak, D. P. ;

Choueiri, T. K. ;

Necchi, A. ;

Gerritsen, W. ;

Gurney, H. ;

Quinn, D. I. ;

Culine, S. ;

Sternberg, C. N. ;

Mai, Y. ;

Poehlein, C. H. ;

Perini, R. F. ;

Bajorin, D. F. .

NEW ENGLAND JOURNAL OF MEDICINE, 2017, 376 (11) :1015-1026

[5]

Bray F, 2018, CA-CANCER J CLIN, V68, P394, DOI [10.3322/caac.21492, 10.3322/caac.21609]

[6] Characteristics, incidence, and risk factors of immune checkpoint inhibitor related pneumonitis in patients with non-small cell lung cancer [J].

Cho, Jun Yeun ;

Kim, Junghoon ;

Lee, Jong Seok ;

Kim, Yu Jung ;

Kim, Se Hyun ;

Lee, Yeon Joo ;

Cho, Young-Jae ;

Yoon, Ho Il ;

Lee, Jae Ho ;

Lee, Choon-Taek ;

Park, Jong Sun .

LUNG CANCER, 2018, 125 :150-156

[7] Immune-checkpoint inhibitors associated with interstitial lung disease in cancer patients [J].

Delaunay, Myriam ;

Cadranel, Jacques ;

Lusque, Amelie ;

Meyer, Nicolas ;

Gounaut, Valerie ;

Moro-Sibilot, Denis ;

Michot, Jean-Marie ;

Raimbourg, Judith ;

Girard, Nicolas ;

Guisier, Florian ;

Planchard, David ;

Metivier, Anne-Cecile ;

Tomasini, Pascale ;

Dansin, Eric ;

Perol, Maurice ;

Campana, Marion ;

Gautschi, Oliver ;

Fruh, Martin ;

Fumet, Jean-David ;

Audigier-Valette, Clarisse ;

Couraud, Sebastien ;

Dalle, Stephane ;

Leccia, Marie-Therese ;

Jaffro, Marion ;

Collot, Samia ;

Prevot, Gregoire ;

Milia, Julie ;

Mazieres, Julien .

EUROPEAN RESPIRATORY JOURNAL, 2017, 50 (02)

[8]

Deng Mi, 2019, Antib Ther, V2, P54, DOI 10.1093/abt/tbz005

[9] Hyperprogressive Disease in Anorectal Melanoma Treated by PD-1 Inhibitors [J].

Faure, Marjorie ;

Rochigneux, Philippe ;

Olive, Daniel ;

Taix, Sebastien ;

Brenot-Rossi, Isabelle ;

Gilabert, Marine .

FRONTIERS IN IMMUNOLOGY, 2018, 9

[10] The Efficacy and Toxicity of Gemcitabine and Cisplatin Chemotherapy in Advanced/Metastatic Bladder Urothelial Carcinoma [J].

Gunlusoy, B. ;

Arslan, M. ;

Vardar, E. ;

Degirmenci, T. ;

Kara, C. ;

Ceylan, Y. ;

Kozacioglu, Z. .

ACTAS UROLOGICAS ESPANOLAS, 2012, 36 (09) :515-520

← 1 2 3 →